Protein-S-100-beta is Increased in Patients with Decompensated Cirrhosis Admitted to ICU

Overview

Journal J Intensive Med

Specialty Critical Care

Date 2024 Apr 29

PMID 38681783

Authors

Nicolas Weiss

Simona Tripon

Maxime Mallet

Francoise Imbert-Bismut

Mehdi Sakka

Dominique Bonnefont-Rousselot

Philippe Sultanik

Sarah Mouri

Marika Rudler

Dominique Thabut

Affiliations

Soon will be listed here.

Abstract

Background: Hepatic encephalopathy (HE) is highly prevalent in patients with liver diseases. The pathophysiology of HE is centered on the synergic role of hyperammonemia and systemic inflammation. However, some data suggest altered functioning of the blood-brain barrier (BBB). Assessing BBB function is challenging in clinical practice and at the bedside. Protein-S-100 Beta (PS100-Beta) could be a useful peripheral marker of BBB permeability in HE. This study aimed to assess plasmatic PS100-Beta levels in a prospective cohort of patients admitted to the intensive care unit (ICU) with decompensated cirrhosis with and without overt HE.

Methods: We retrospectively evaluated a prospective cohort of cirrhotic patients admitted to the ICU from October 2013 to September 2015 that had an available plasmatic PS100-Beta measurement. Patients with previous neurological impairment or limitation of intensive or resuscitative measures were excluded. Overt HE was defined as West-Haven grades 2 to 4. The patients were compared to a control cohort of outpatient clinic cirrhotic and non-cirrhotic patients explored for isolated elevation of liver enzymes. After ICU discharge, the patients were followed for at least 3 months for the occurrence of overt HE. Adverse outcomes (liver transplantation or death) were collected. The ability of PS100-Beta - in combination with other factors - to predict overt HE was evaluated in a multivariate analysis using logistic regression. Likelihood ratios were used to determine the effects and calculate odds ratios (OR). Survival analysis was performed by using the Kaplan-Meier method and survival between groups was compared using a Log-rank test.

Results: A total of 194 ICU patients and 207 outpatients were included in the study. Increased levels of plasmatic PS100-Beta were detected in the ICU decompensated cirrhotic patients compared with the outpatients ([0.15±0.01] mg/L [0.08±0] mg/L, <0.001). ICU patients with overt HE had higher levels of PS100-Beta ([0.19±0.03] mg/L) compared with the ICU patients without overt HE ([0.13±0.01] mg/L) (=0.003). PS100-Beta levels did not differ in outpatients with F 0-3 compared to F 4 fibrosis (0.670). PS100-Beta values were correlated with Child-Pugh score (0.001), Model for End-Stage Liver Disease (MELD) score (0.004), C-reactive protein (0.001), ammonemia (0.001), and chronic liver failure consortium (CLIF-C) organ failure (0.001) and CLIF-C acute-on-chronic (0.038) scores, but not with leukocytes (0.053), procalcitonin (PCT) (0.107), or the lymphocyte-to-neutrophil ratio in ICU patients (0.522). In a multivariate model including age, ammonemia, PS100-Beta, PCT, MELD, presence of transjugular portosystemic shunt, and sodium level, the diagnostic performance was 0.765 for the diagnosis of overt HE. Patients with a PS100-Beta level <0.12 mg/L had a better overall survival (0.019) and a better survival without liver transplantation (0.013).

Conclusions: Serum levels of PS100-Beta are elevated in ICU patients with decompensated cirrhosis, and even more so in those displaying overt HE, and the levels are correlated with outcome. This suggests an increase in the permeability of the BBB in these patients.

Citing Articles

Ammonia and beyond - biomarkers of hepatic encephalopathy.

Gallego J, Ballester M, Fiorillo A, Casanova-Ferrer F, Lopez-Gramaje A, Urios A Metab Brain Dis. 2025; 40(1):100.

PMID: 39812958 PMC: 11735499. DOI: 10.1007/s11011-024-01512-7.

References

Hanin A, Lambrecq V, Denis J, Imbert-Bismut F, Rucheton B, Lamari F . Cerebrospinal fluid and blood biomarkers of status epilepticus. Epilepsia. 2019; 61(1):6-18. DOI: 10.1111/epi.16405. View

Weiss N, Sanchez-Pena P, Roche S, Beaudeux J, Colonne C, Coriat P . Prognosis value of plasma S100B protein levels after subarachnoid aneurysmal hemorrhage. Anesthesiology. 2006; 104(4):658-66. DOI: 10.1097/00000542-200604000-00008. View

Bouzbib C, El Mourabit H, Wendum D, Lasnier E, Mouri S, Housset C . ATP-binding cassette transporters expression in rats with cirrhosis and hepatic encephalopathy. Clin Res Hepatol Gastroenterol. 2021; 46(9):101784. DOI: 10.1016/j.clinre.2021.101784. View

Mongardon N, Arnaout M, Geri G, Chenevier-Gobeaux C, Deye N, Legriel S . Usefulness of early plasma S-100B protein and Neuron-Specific Enolase measurements to identify cerebrovascular etiology of out-of-hospital cardiac arrest. Resuscitation. 2018; 130:61-66. DOI: 10.1016/j.resuscitation.2018.07.004. View

Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T . Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001; 357(9262):1069-75. DOI: 10.1016/S0140-6736(00)04258-6. View

Laribi S, Kansao J, Borderie D, Collet C, Deschamps P, Ababsa R . S100B blood level measurement to exclude cerebral lesions after minor head injury: the multicenter STIC-S100 French study. Clin Chem Lab Med. 2013; 52(4):527-36. DOI: 10.1515/cclm-2013-0621. View

Imbert-Bismut F, Payet P, Alfaisal J, Munteanu M, Rudler M, Sultanik P . Transportation and handling of blood samples prior to ammonia measurement in the real life of a large university hospital. Clin Chim Acta. 2020; 510:522-530. DOI: 10.1016/j.cca.2020.07.048. View

Pancotto T, Rossmeisl Jr J, Panciera D, Zimmerman K . Blood-brain-barrier disruption in chronic canine hypothyroidism. Vet Clin Pathol. 2010; 39(4):485-93. DOI: 10.1111/j.1939-165X.2010.00253.x. View

Kalra A, Wedd J, Bambha K, Gralla J, Golden-Mason L, Collins C . Neutrophil-to-lymphocyte ratio correlates with proinflammatory neutrophils and predicts death in low model for end-stage liver disease patients with cirrhosis. Liver Transpl. 2016; 23(2):155-165. PMC: 5529041. DOI: 10.1002/lt.24702. View

10.

Schaefer A, Journaux M, El Mourabit H, Mouri S, Wendum D, Lasnier E . A systemic mechanism of increased transendothelial migration of leukocytes through the blood-brain barrier in hepatic encephalopathy. Clin Res Hepatol Gastroenterol. 2021; 46(3):101801. DOI: 10.1016/j.clinre.2021.101801. View

11.

Oertel M, Schumacher U, McArthur D, Kastner S, Boker D . S-100B and NSE: markers of initial impact of subarachnoid haemorrhage and their relation to vasospasm and outcome. J Clin Neurosci. 2006; 13(8):834-40. DOI: 10.1016/j.jocn.2005.11.030. View

12.

Pham N, Fazio V, Cucullo L, Teng Q, Biberthaler P, Bazarian J . Extracranial sources of S100B do not affect serum levels. PLoS One. 2010; 5(9). PMC: 2937027. DOI: 10.1371/journal.pone.0012691. View

13.

Peric B, Zagar I, Novakovic S, Zgajnar J, Hocevar M . Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma. BMC Cancer. 2011; 11:328. PMC: 3162584. DOI: 10.1186/1471-2407-11-328. View

14.

Shawcross D, Wright G, Olde Damink S, Jalan R . Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis. 2007; 22(1):125-38. DOI: 10.1007/s11011-006-9042-1. View

15.

Mouri S, Tripon S, Rudler M, Mallet M, Mayaux J, Thabut D . FOUR score, a reliable score for assessing overt hepatic encephalopathy in cirrhotic patients. Neurocrit Care. 2014; 22(2):251-7. DOI: 10.1007/s12028-014-0078-5. View

16.

Kruijff S, Bastiaannet E, Muller Kobold A, van Ginkel R, Suurmeijer A, Hoekstra H . S-100B concentrations predict disease-free survival in stage III melanoma patients. Ann Surg Oncol. 2009; 16(12):3455-62. PMC: 2779363. DOI: 10.1245/s10434-009-0629-8. View

17.

Kirchhoff C, Buhmann S, Braunstein V, Leidel B, Vogel T, Kreimeier U . Cerebrospinal s100-B: a potential marker for progressive intracranial hemorrhage in patients with severe traumatic brain injury. Eur J Med Res. 2008; 13(11):511-6. View

18.

Bajaj J, Khoruts A . Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis. J Hepatol. 2020; 72(5):1003-1027. DOI: 10.1016/j.jhep.2020.01.017. View

19.

Shawcross D, Davies N, Williams R, Jalan R . Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol. 2004; 40(2):247-54. DOI: 10.1016/j.jhep.2003.10.016. View

20.

Weiss N, Rosselli M, Mouri S, Galanaud D, Puybasset L, Agarwal B . Modification in CSF specific gravity in acutely decompensated cirrhosis and acute on chronic liver failure independent of encephalopathy, evidences for an early blood-CSF barrier dysfunction in cirrhosis. Metab Brain Dis. 2016; 32(2):369-376. DOI: 10.1007/s11011-016-9916-9. View